These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25888611)

  • 1. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.
    Chen TW; Razak AR; Bedard PL; Siu LL; Hansen AR
    Ann Oncol; 2015 Sep; 26(9):1824-1829. PubMed ID: 25888611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
    Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
    Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Event Reporting Quality in Cancer Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy: A Systematic Review.
    Wang Y; Chen C; Du W; Zhou Y; He L; Hong S; Zhang L
    Front Immunol; 2022; 13():874829. PubMed ID: 35874673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review.
    Malone E; Barua R; Meti N; Li X; Fazelzad R; Hansen AR
    Cancer Med; 2021 Aug; 10(15):5031-5040. PubMed ID: 34184416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
    Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
    Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
    Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
    J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer.
    Chen C; Zhou Y; Zhang X; Wang Y; He LN; Lin Z; Chen T; Jiang Y; Hong S; Zhang L
    Front Immunol; 2021; 12():736943. PubMed ID: 34675926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors.
    Karimian Z; Mavoungou S; Salem JE; Tubach F; Dechartres A
    BMC Cancer; 2020 Nov; 20(1):1128. PubMed ID: 33225901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
    Cappelli LC; Gutierrez AK; Bingham CO; Shah AA
    Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.
    Arnaud-Coffin P; Maillet D; Gan HK; Stelmes JJ; You B; Dalle S; Péron J
    Int J Cancer; 2019 Aug; 145(3):639-648. PubMed ID: 30653255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse event reporting in cancer clinical trial publications.
    Sivendran S; Latif A; McBride RB; Stensland KD; Wisnivesky J; Haines L; Oh WK; Galsky MD
    J Clin Oncol; 2014 Jan; 32(2):83-9. PubMed ID: 24323037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.
    Gao L; Yang X; Yi C; Zhu H
    Front Pharmacol; 2019; 10():1173. PubMed ID: 31680957
    [No Abstract]   [Full Text] [Related]  

  • 17. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events reporting in phase 3 oncology clinical trials of checkpoint inhibitors: A systematic review.
    Barhli A; Joulia ML; Tournigand C; Kempf E
    Crit Rev Oncol Hematol; 2021 Jan; 157():103162. PubMed ID: 33260049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
    Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
    Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
    Sato K; Mano T; Iwata A; Toda T
    J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.